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Variability in antifungal utilization among
neonatal, pediatric, and adult inpatients in
academic medical centers throughout the
United States of America
Jeremy S. Stultz1* , Rose Kohinke2 and Amy L. Pakyz3
Abstract
Background: Identification of factors associated with antifungal utilization in neonatal, pediatric, and adult patient
groups is needed to guide antifungal stewardship initiatives in academic medical centers.
Methods: For this hospital-level analysis, we analyzed antifungal use in hospitals across the United States of
America, excluding centers only providing care for hematology/oncology patients. Analysis of variance was used to
compare antifungal use between patient groups. Three multivariable linear regression models were used to
determine independent factors associated with antifungal use in the neonatal, pediatric, and adult patient groups.
Results: For the neonatal, pediatric, and adult patient groups, 54, 44, and 60 hospitals were included, respectively.
Total antifungal use was significantly lower in the neonatal patient group (14 days of therapy (DOT)/1000 patient
days (PDs) versus 76 in pediatrics and 74 in adults, p < 0.05). There were no significant associations identified with
total antifungal DOT/1000 PDs in the neonatal patient group (model R2 = 0.11). In the pediatric patient group
(model R2 = 0.55), admission to immunosuppressed service lines and total broad-spectrum antibiotic use were
positively associated with total antifungal use (coefficients of 1.95 and 0.41, both p < 0.05). In the adult patient
group (model R2 = 0.79), admission to immunosuppressed service lines, total invasive fungal infections, and total
broad-spectrum antibiotic use were positively associated with total antifungal use (coefficients of 5.08, 5.17, and
0.137, all p < 0.05).
Conclusions: Variability in antifungal use in the neonatal group could not be explained well, whereas factors were
associated with antifungal use in the adult and pediatric patient groups. These data can help guide antifungal
stewardship initiatives.
Keywords: Antimicrobial stewardship, Pediatrics, Neonates, Antifungal stewardship, Antimicrobial trends
Background
Invasive fungal infections (IFIs) are recognized compli-
cations that can cause significant morbidity and mortal-
ity in immunosuppressed and critically ill neonatal,
pediatric and adult patients [1–3]. Similar to antibiotics,
frequent use of common antifungal agents has been
associated with increased resistance in adults, which
could pose a challenge to the effective management of
IFIs [4, 5]. Recent trends have suggested there are
increasing rates of non-Candida albicans species caus-
ing IFIs, which may have more resistance to the com-
monly used antifungal, fluconazole [3]. Appropriate and
judicious use of antifungals may help preserve the utility
of currently available antifungals in treating IFIs. In the
2016 Infectious Diseases Society of America (IDSA)/ So-
ciety for Healthcare Epidemiology of America (SHEA)
recommendations regarding Antimicrobial Stewardship
(ASP) implementation, ASP interventions for immuno-
compromised patients receiving antifungal therapy are
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recommended [6]. This recommendation was based on a
low quality of evidence.
Published antifungal stewardship interventions have
included activities such as prior authorization, restric-
tions, and prospective audits with feedback. Most of
these studies occurred at single institutions [5, 7–10].
Additional studies are needed to guide antifungal stew-
ardship practices across multiple institutions. Antifungal
usage trends and factors associated with use in United
States of America (US) academic medical centers
(AMCs) have been described in adults [11]. This prior
study utilized data from 2004 to 2008 and antifungal
utilization and antifungal stewardship practices may have
changed since then, necessitating additional analysis.
The pediatric and neonatal populations have unique
ASP needs and IFI etiology, which will alter the needs of
age-specific antifungal stewardship initiatives [1, 12, 13].
The IDSA/SHEA ASP implementation guidelines sug-
gest that although ASP activities may not have been
studied to the same extent in the pediatric population
compared to the adult population, the activities are likely
effective and should be implemented. The guidelines
also recommend antibiotic stewardship in neonates, but
do not mention antifungal stewardship in this setting
[6]. Additional analysis is needed to effectively construct
ASP and antifungal stewardship activities in the pediatric
population. Freestanding children’s hospitals may have
differences in antifungal use and/or ASP practices com-
pared to an AMC (i.e., a pediatric hospital housed within
an adult hospital) where pediatric and neonatal policies
are more likely to be extensions of adult policies. Trends
in antifungal use over time have been previously
described among freestanding pediatric US institutions,
but not in pediatric hospitals within an AMC [14].
Additionally, factors associated with antifungal use have
not been identified in the pediatric population. Thus,
there is limited data in AMCs to determine antifungal
usage patterns and guide potential pediatric and neo-
natal antifungal stewardship activities.
The objectives of our study of AMCs across the US
were multifold. First, we wanted to describe antifungal
use in the neonatal, pediatric, and adult patient groups.
Second, we aimed to identify antifungal stewardship
targets by evaluating factors associated with antifungal
use in neonatal, pediatric, and adult patients. As a
tertiary aim, we sought to identify if antifungal restric-
tion impacted antifungal use.
Methods
Hospital data source
The data for this hospital-level cross-sectional analysis
were obtained from Vizient, an alliance of US hospitals,
inclusive of AMCs. Data were obtained for AMCs from
the Clinical Data Base Resource Manager (CDB/RM) of
Vizient. The CDB/RM includes charge-based inpatient
medication, procedure, and diagnosis specific data. Data
obtained from the CDB/RM have been utilized in previ-
ous studies regarding antimicrobial use [11, 15]. Vizient
hospitals are located in all major US geographic regions.
Information was collected from Vizient members that
consistently reported data from January 1, 2015 through
December 31, 2015.
Data collection
Data were collected for three separate patient groups:
adult inpatients (≥18 years), pediatric inpatients (<
18 years excluding the neonatology service), and neo-
nates/infants classified under the neonatal service line.
Normal newborns were excluded from the analysis due
to lack of antifungal use. Centers only providing care for
hematology/oncology patients (n = 5) and those hospitals
with no reported use of any target agents were excluded.
Within each identified patient group, systemic antifun-
gal use was measured for azoles (fluconazole, itracona-
zole, voriconazole, and posaconazole), echinocandins
(caspofungin, micafungin, and anidulafungin), and poly-
enes (amphotericin B deoxycholate, liposomal amphoter-
icin B, and amphotericin B lipid complex). Agents that
are only intended for topical use or only as combination
therapy (i.e., flucytosine) were excluded. Usage was
expressed as days of therapy (DOT) normalized per
1000 patient-days (PD). One DOT represented the
receipt of an antifungal agent on a given day, regardless
of the strength, number of doses, or route of administra-
tion. Average length of therapy (LOT) was also deter-
mined in days, but was not normalized since patient
level data was not available.
Potential factors associated with antifungal use were
measured for the three patient groups from the CDB/
RM. The frequency of International Classification of
Diseases version 9 (ICD-9) codes for an IFI was mea-
sured as admissions/1000 PD. All relevant 112, 114, 115,
116, and 117 codes excluding mucosal or superficial in-
fections were included. The number of DOT/1000 PD of
broad-spectrum antibiotics (defined as carbapenems,
intravenous third- or fourth-generation cephalosporins,
and antipseudomonal β-lactam/ β-lactamase inhibitor
combinations and fluoroquinolones) was measured, as
antibiotics have served as an independent risk factor for
candidemia [16, 17]. Geographic location of the institu-
tion was collected (i.e., Northeast, South, Midwest,
West). Data concerning clinical service line (CSL) distri-
butions within the pediatric and adult patient groups
were obtained and measured as PD admitted to the ser-
vice line/1000 PD. The 32 different Vizient CSLs were
collapsed into four categories: medicine; surgery; and
immunosuppressed (e.g., oncology, transplant); and other.
The number of extremely low birthweight neonates,
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defined as a birthweight of < 1000 g, was collected for the
neonatal patient group since fluconazole prophylaxis may
be considered in these patients [18]. To account for the
level of neonatal care provided, institutions with at least
one extracorporeal membrane oxygenation (ECMO) case
in 2015 were categorized as ECMO centers. The neo-
natal intensive care unit levels 1–4 were not used as
variation in level definition occurs between states. Fi-
nally, data concerning the extent of ASP involvement
at the institution were obtained from a previously
administered survey concerning ASPs as described in
the following section.
Antimicrobial stewardship questionnaire
A survey requesting information regarding antimicrobial
stewardship practices was sent via email in March 2016
to Vizient members through the Vizient antimicrobial
stewardship list-serve. Two questions from this survey
were used for this study. One question was utilized as a
possible factor related to antifungal use. It asked institu-
tions how often they performed post-prescription ntibio-
tic review across seven different adult hospital service
line categories and in pediatric and neonatal intensive
care unit (NICU) populations. The answer options were:
always/almost always; more than half the time; one-
quarter of the time; not currently performed; and not
applicable. This question was included to approximate
the extent of an institution’s ASP. For analytical purposes,
institutions were categorized as having extensive ASP
involvement or not. In the adult analysis, extensive ASP
involvement was defined as performing post-prescription
review half of the time or more in five main service lines
(medical intensive care unit (ICU), surgical ICU, surgical
units, non-ICU medical floors, and oncology). The other
two service lines (obstetrics/gynecology and rehabilitation)
were not included in the definition due to low ASP
activities being performed across institutions in those
areas. In the pediatric and neonatal analysis, any response
of an institution performing pediatric or neonatal post-
prescription review half the time or more was considered
extensive.
A second survey question was included to help achieve
our tertiary study objective. It asked if an echinocandin,
usually caspofungin or micafungin, was on the hospital’s
formulary and if use was restricted. Antifungal use data
were compiled based on echinocandin restriction for
comparison. Hospitals were excluded from this analysis
if they did not answer this survey question or did not
have a matching hospital that fulfilled other inclusion
criteria. This question was not included as a potential
factor for antifungal use, because the survey question
did not specify to which of the patient groups the
restrictions applied.
Statistical analysis
Descriptive statistics utilized were mean with standard
deviation (SD) or 95% confidence interval. Analysis of
variance with post-hoc Tukey analysis was performed to
compare antifungal usage trends between the three
patient groups. To identify the factors associated with
total antifungal use for each patient group we performed
three linear regression analyses, one for each patient
group. Univariable linear regression was performed on
all potential explanatory factors collected as part of this
study and any factors with a significance level of < 0.25
on univariable analysis were then included in a multivar-
iable linear regression model. Variance inflation factors
were evaluated to assess for collinearity. For antifungal
use comparisons between hospitals restricting echino-
candins and those not restricting echinocandins, the
T-test or Wilcoxon rank sum test was used based on
data normality and sample size. All tests were two-tailed
when applicable and the significance level was set at
0.05. All statistical tests were performed using JMP
software (JMP Pro 13; SAS Institute, Inc., Cary, NC)
with the exclusion of regression analyses, for which
STATA software (version 13; Stata Corporation, College
Station, TX) was used.
Results
Hospital characteristics
Complete medication data for 2015 and survey re-
sponses were available for 54, 44, and 60 of the hospitals
for neonatal, pediatric, and adult patient groups, respect-
ively. This represented over 2.1 million patient admis-
sions. Table 1 provides additional details regarding
hospital characteristics based on patient group. Medicine
service lines represented the most patient days in the
pediatric and adult population, and broad-spectrum
antibiotic use was higher in the pediatric and adult
patient groups compared to the neonatal population.
Adults represented the largest patient group based on
admissions and had the most IFIs based on ICD-9 codes.
For over 50% of the surveyed institutions, ASP activity
was considered extensive (Table 1).
Antifungal use among patient groups
Table 2 provides details regarding antifungal use for each
of the patient groups. The most commonly used antifun-
gal in all patient groups was fluconazole, which encom-
passed 85% of antifungal use in the neonatal group.
Voriconazole and micafungin were the next most
common antifungals used in the pediatric and adult
group (13–16% of use in these two groups), although
both agents had less use in the neonatal group (Table 2).
For all azole antifungals, the mean (SD) LOTs were 7.6
(3.3), 7.7 (2.9), and 6.5 (1.5) days for the neonatal,
pediatric, and adult groups, respectively (p = 0.0383).
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The mean (SD) LOTs for amphotericin B products were
7.8 (8.9), 12.3 (8.7), and 7.5 (2.6) days for the neonatal,
pediatric, and adult groups, respectively (p = 0.0118).
Post-hoc Tukey analysis suggested the pediatric patient
group had longer LOT than both the neonatal and adult
group (both p < 0.05). The mean (SD) LOTs for the echi-
nocandin class were 13.9 (16), 12.5 (5.1), and 8 (1.6) days
for the neonatal, pediatric, and adult groups, respectively
(p = 0.0014). Post-hoc Tukey analysis suggested the adult
group had significantly shorter LOT than the neonatal
and pediatric groups (both p < 0.05).
There were significant differences in the mean total
antifungal use (expressed as DOT/1000 PD) and
class-specific antifungal use among the patient groups.
Based on post-hoc Tukey analysis, the antifungal DOT/
1000 PD means were generally the same between the
adult and pediatric patient groups, and significantly less
in the neonatal group compared to adults and pediatrics
(all p < 0.007, Table 2).
Factors related to antifungal use
Table 3 provides details regarding the univariable and
multivariable linear regression analyses. The neonatal
group model did not explain well the variation in anti-
fungal use between institutions (R2 = 0.11) despite utiliz-
ing the log DOT/1000 PD, while the adult and pediatric
patient group models respectively explained 55% and
79% of the variation. In the neonatal patient group, total
IFIs, being an ECMO center, and broad-spectrum
antibiotic use had significant positive associations with
antifungal use on univariable analysis, although none of
these factors had significant associations on multivari-
able analysis. The pediatric patient group had significant
negative associations with antifungal use in medicine
and surgical service lines and positive associations for
immunosuppressed service lines and total broad-
spectrum antibiotic use upon multivariable analysis (all
p < 0.05). The associations with surgery service lines was
only found on multivariable analysis. The adult pa-
tient group had significant and positive correlations
with antifungal use and immunosuppressed service
lines, total IFIs, and total broad-spectrum antibiotic
use (all p < 0.015).
Impact of Echinocandin restriction
Table 4 compares the institutions overall that restricted
echinocandin use on their hospital formulary with hospi-
tals that did not restrict echinocandin use. When includ-
ing all three patient groups, there was no difference in
the antifungal utilization or total IFIs. If only the adult
patient group was examined, there was a significantly
higher use of all antifungals at institutions that restricted
echinocandins (p < 0.001) and no difference in total IFIs.
Table 1 Characteristics of hospitals based on patient group
Characteristic Neonates: n = 54;
100,155 admissions
Pediatrics: n = 44;
159,936 admissions
Adults: n = 60;
1,841,667 admissions
Geographic region, no. (%)
South 17 (31) 15 (34) 17 (28)
Midwest 14 (26) 12 (27) 17 (28)
Northeast 13 (24) 9 (21) 13 (22)
West 10 (19) 8 (18) 13 (22)
CSL mean PD/1000 PD (SD)
Medicine NA 132 (55) 73 (17)
Surgery NA 72 (27) 57 (13)
Immunosuppressed NA 18 (9) 12 (4)
Other NA 35 (43) 31 (13)
Patient mix, mean admissions/1000 PD (SD)
Total invasive fungal infections 0.5 (0.9) 0.8 (1.4) 4.7 (2.6)
Extremely low birthweight 19 (18) N/A N/A
Patient mix, mean % (SD)
Group admissions per total hospital admissions 5 (1.5) 10 (5) 89 (10)
Broad spectrum antibiotic use, DOT/1000 PD (SD) 84 (97) 273 (90) 283 (55)
Extensivea ASP, no. (%) 36 (67) 26 (59) 32 (53)
CSL clinical service line, PD patient days, DOT days of therapy, ASP antimicrobial stewardship program
a Defined for adult group as performing ASP half of the time or more in 5 main service lines (medical intensive care unit (ICU), surgical ICU, surgical units, non-ICU
medical floors, and oncology). For pediatric and neonatal groups, any response of an institution performing pediatric or neonatal ASP half the time or more was
considered extensive ASP activities
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Discussion
This study provides a unique analysis of antifungal
utilization within AMCs in the neonatal, pediatric, and
adult patient groups and identified factors associated
with antifungal use. These data can help guide antifungal
stewardship initiatives in the pediatric and neonatal
patient groups at AMCs where such programs may be
less frequently implemented.
These data showed that fluconazole remained the
most commonly used antifungal in 2015 at the included
hospitals among all patient groups, followed by vorico-
nazole and micafungin in the adult and pediatric groups.
Conventional amphotericin B was the second most
highly used antifungal in the neonatal group, although
closely followed by micafungin. Compared to a study
from the same database performed in 2004–2008, adult
utilization was similar except for a decrease in overall
amphotericin use (5.1 DOT/1000 PD in 2008 to 3.9 in
2015), an increase in echinocandin use with a switch
from caspofungin predominance to micafungin predom-
inance (13.1 DOT/1000 PD to 14.3), and a decrease in
voriconazole use (14 DOT/1000 PD to 10) [11]. Recent
analyses using a different database have shown a similar
trend of increasing echinocandin usage since 2006 in
adults [19].
In a previous study of US freestanding children’s
hospitals from 2000 to 2006, echinocandin percent
utilization was the same or less than amphotericin B
products, itraconazole was minimally used and posaco-
nazole suspension was not FDA approved until 2006
[14]. Echinocandins were used more in our study in the
pediatric population than amphotericin B products and
posaconazole and itraconazole did have some use. These
data suggest antifungal use is changing away from
amphotericin B products compared to previous studies
in the pediatric and adult patient groups. In the neonatal
patient group, there was minimal use of echinocandins
in 2006 in the previous study in freestanding children’s
hospitals and while our study did have greater echino-
candin use, amphotericin B still had higher use [14]. It is
important to note that our study had different method-
ology and there was a 10-year difference between our
study and prior studies. While not all antifungals are
currently approved by the US Food and Drug adminis-
tration for use in neonatal and pediatric patients, some
changes in FDA approval status (e.g., caspofungin) and
increased clinical studies and experience over the
10-year timeframe could explain some of the differences
in antifungal use. Additionally, different study method-
ologies and possible differences between freestanding
children’s hospitals and AMCs could explain differences
between these studies. A future study could aim to
compare use in freestanding hospitals to AMCs during
similar timeframes.
A recent analysis of antifungal usage in 2015 among
US freestanding children’s hospitals also suggested that
echinocandin use was higher than amphotericin B [20].
This study did not separate the neonatal population and
only included the oncology, bone marrow transplant,
and solid organ transplant population. In 2012, a single
day point prevalence study completed in 226 European
centers found opposing results compared to studies,
Table 2 Antifungal use among hospitals based on patient group
Antifungal agent Neonates: n = 54;
100,155 admissions
Pediatrics: n = 44;
159,936 admissions
Adults: n = 60;
1,841,667 admissions
ANOVA (F-statistic)
Total antifungals* 14.4 (10.7 to 18.2) 75.8 (56.6 to 95.1) 73.2 (62.7 to 84.4) p < 0.001 (34.8)
Azoles* 12.3 (8.6 to 15.6) 54.6 (40.8 to 68.4) 55.1 (47.2 to 63.4) p < 0.001 (32.7)
Fluconazole 12.2 (8.8 to 15.6) 40.6 (31.7 to 49.4) 37.9 (33.3 to 42.4)
Voriconazole 0.03 (− 0.03 to 0.09) 12.5 (6 to 19) 10 (7.8 to 12.3)
Posaconazole 0 0.91 (− 0.02 to 1.8) 5.8 (3.4 to 8.3)
Itraconazole 0 0.61 (0.12 to 1.1) 1.3 (0.58 to 2.1)
Amphotericin B* 1.4 (0.71 to 2.1) 3.8 (1.9 to 5.7) 3.9 (3.0 to 4.8) p = 0.0021 (6.1)
Conventional 0.66 (0.23 to 1.1) 0.78 (− 0.07 to 1.6) 1.3 (0.76 to 1.9)
Liposomal 0.25 (0.03 to 0.47) 2.3 (0.72 to 3.9) 2.1 (1.5 to 2.6)
Lipid complex 0.5 (−0.018 to 1.02) 0.72 (− 0.002 to 1.43) 0.5 (0.24 to 0.78)
Echinocandins* 0.76 (0.32 to 1.2) 17.4 (11.4 to 23.5) 14.3 (11.8 to 16.8) p < 0.001 (28)
Caspofungin 0.17 (−0.005 to 0.34) 4.9 (0.5 to 9.3) 2.9 (1.2 to 4.6)
Micafungin 0.59 (0.21 to 0.98) 12.5 (7.3 to 17.8) 10.4 (7.9 to 12.9)
Anidulafungin 0 0 1 (0.4 to 1.7)
ANOVA, analysis of variance
All data presented as mean (95% CI) days of therapy/1000 patient days
*Mean days of therapy/1000 patient days was statistically different between the neonatal group and the adult and pediatric group on post-hoc Tukey analysis, all
p < 0.01, no significant differences occurred between the pediatric and adult groups, all p > 0.12
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including ours, from the US. When combining neonate
and pediatric patients in this study, conventional ampho-
tericin B was the second most utilized medication at
30% of the prescribed medications (only 5–8% of use in
our study for pediatric and neonatal patient groups) and
echinocandins were only used 10% of the time [21]. This
suggests there are likely differing practices between
countries regarding antifungal use in addition to
variations within a country as noted in our study and
other analyses [20].
The pediatric and neonatal groups generally had
longer LOT compared to adult groups, with notable
differences of about 3–5 days for the echinocandin class.
It was not possible from this data to determine why this
occurred and this could be an area for additional
research. Stewardship programs reviewing antifungal use
Table 3 Linear regression models for factors associated with antifungal use
Variable Univariable Multivariable
Coefficient (95% CI) Standard error p-value Coefficient (95% CI) Standard error p-value
Neonates (R2 adjusted =0.11)a: n = 54 institutions; 100,155 admissions
ELBW admissions 0.016 (− 0.002 to 0.035) 0.009 0.083 −0.011 (− 0.039 to 0.016) 0.014 0.418
Total invasive fungal infections 0.442 (0.107 to 0.777) 0.167 0.011 0.375 (−0.185 to 0.935) 0.279 0.185
Total broad-spectrum antibiotics 0.005 (0.001 to 0.009) 0.002 0.012 0.002 (−0.003 to 0.007) 0.002 0.414
Extracorporeal membrane oxygenation
center
0.899 (0.275 to 1.52) 0.311 0.006 0.494 (− 0.305 to 1.29) 0.397 0.220
Region (referent group = Northeast) – –
South 0.864 (−0.016 to 1.75) 0.438 0.054 0.278 (−0.743 to 1.30) 0.507 0.587
Midwest 0.522 (−0.399 to 1.44) 0.458 0.260 0.391 (−0.54 to 1.32) 0.462 0.402
West 0.006 (−0.999 to 1.01) 0.500 0.991 −0.256 (1.25 to 0.737) 0.493 0.606
Pediatrics (R2 adjusted =0.55): n = 44 institutions; 159,936 admissions
Medicine service lines admissions −0.35 (− 0.69 to − 0.01) 0.168 0.044 −0.35 (− 0.658 to-0.045) 0.151 0.026
Immunosuppressed service lines admissions 2.08 (0.055 to 4.1) 1.00 0.044 1.95 (0.061 to 3.84) 0.932 0.043
Surgery service lines −0.573 (−1.27 to 0.12) 0.345 0.104 −1.05 (−1.75 to − 0.345) 0.347 0.005
Total invasive fungal infections 10.1 (−3.54 to 23.7) 6.76 0.142 1.75 (−8.62 to 12.1) 5.11 0.733
Total broad-spectrum antibiotic use 0.327 (0.135 to 0.521) 0.095 0.001 0.41 (0.254 to 0.572) 0.075 < 0.001
Region (referent group = Northeast) – –
South 21.2 (−32 to 75) 26.6 0.430 −11.9 (−53.9 to 30) 20.6 0.568
Midwest 47.2 (−9.1 to 103) 27.8 0.099 23.7 (−19.3 to 66.7) 21.1 0.279
West 34.8 (−27 to 97) 30.7 0.264 42.6 (−2.27 to 87.5) 22.1 0.062
Adults (R2 adjusted =0.79): n = 60 institutions; 1,841,667 admissions
Medicine service lines admissions −1.255 (−1.8 -to −0.70) 0.27 < 0.001 −0.311 (−0.724 to 0.102) 0.21 0.137
Immunosuppressed service lines admissions 8.03 (8.03 to 9.61) 0.79 < 0.001 5.08 (3.56 to 6.6) 0.76 < 0.001
Total invasive fungal infections 12.4 (9.65 to 15.2) 1.34 < 0.001 5.17 (1.82 to 8.52) 1.7 0.003
Total broad-spectrum antibiotics 0.345 (0.167 to 0.523) 0.89 < 0.001 0.137 (0.032 to 0.242) 0.05 0.011
Extensiveb ASP (referent = not extensive ASP) 21.4 (−0.263 to 43) 10.8 0.053 2.75 (−8.14 to 13.6) 5.4 0.614
Region (referent group = Northeast) – –
South 9.12 (−21.4 to 39.7) 15.3 0.552 −9.65 (− 24 to 5.4) 7.5 0.204
Midwest 12.2 (−18.3 to 42.8) 15.3 0.425 2.25 (−12.8 to 17.3) 7.5 0.764
West 33.9 (1.38 to 66.5) 16.2 0.041 4.84 (−12 to 22) 5.4 0.569
ELBW extremely low birthweight < 1000 g, ASP antimicrobial stewardship program
Data normalized as admissions/1000 patient admissions or days of therapy/1000 patient days when appropriate
Table only includes variables with p < 0.25 on univariable analysis
a log days of therapy/1000 patient days was utilized
b Defined for adult group as performing ASP half of the time or more in 5 main service lines (medical intensive care unit (ICU), surgical ICU, surgical units, non-ICU
medical floors, and oncology). For pediatric and neonatal groups, any response of an institution performing pediatric or neonatal ASP half the time or more was
considered extensive ASP activities
Bolded p-values were statistically significant
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in pediatric patients may want to focus on assessment of
appropriate treatment durations.
There were some interesting differences among the
factors associated with antifungal use between the
pediatric and adult populations. Analysis of associated
factors for antibiotic and antifungal use has been
performed previously in adults to identify ASP targets
[11, 15], but in the pediatric and neonatal populations
similar analyses have only been completed for antibiotics
[5, 22]. Our study did not identify any associations with
use in the neonatal group on multivariable analysis
(Table 3). Invasive fungal infections determined by
ICD-9 codes were not associated with antifungal use in
this group, which suggests either ICD-9 codes are not
accurate in these patient groups or that most of the use
in this population is for empiric therapy or prophylaxis
[18]. Our inability to identify any factors could also be a
result of not including other clinical factors (e.g., central
line access, parenteral nutrition, corticosteroid use).
However, extremely low birthweight was included and
this factor is the main reason to consider antifungal
prophylaxis in the neonatal population based on the
IDSA guideline [18, 23].
Our results in the neonatal patient group most likely
suggest that there are wide practice variations among
pediatric hospitals within AMCs, which has been
described for antibiotic use in children and in other
patient populations receiving antifungals [5, 24, 25]. The
large variability noted in neonatal antifungal practices
despite controlling for multiple possible factors high-
lights that AMC stewardship programs should consider
reviewing these populations to ensure use is appropriate.
Due to the likely low number of cases, this could be an
area for review of appropriateness on a daily basis. The
IDSA ASP guidelines do not specify whether antifungal
stewardship should be employed in the NICU popula-
tion [6], but our study suggests antifungal in addition to
antimicrobial stewardship is needed in AMC NICUs.
The pediatric and adult patient groups had more iden-
tified factors for antifungal utilization (Table 3). This
suggests more consistent practices exist between institu-
tions in these patient groups, despite higher use. Invasive
fungal infections based on ICD-9 codes had a positive
association in the adult populations and suggests treat-
ment for fungal infections was more common in this
population. The association between broad-spectrum
antibiotic use and antifungal use identified in the
pediatric and adult groups has been previously described
and is of concern [11]. It is possible this finding is only
an identified factor due to disease severity instead of
causation and more analysis is needed. Identification of
immunosuppressed service lines as an associated factor
for antifungal use in the pediatric and adult groups
suggests institutions should review antifungal regimens
among these patients to ensure appropriate use. Guide-
line development, periodic utilization reviews, or anti-
fungal restrictions may be more feasible stewardship
initiatives versus daily review due to a higher volume of
use among the immunosuppressed.
In our study, we sought to determine if there was a
link between the extent of ASP involvement and antifun-
gal use by two different analyses. The reported use of
post-prescription review more than half of the time in
multiple locations within the hospital (or at all in the
pediatric and neonatal groups) was included in our
linear regression models, but was not found to be associ-
ated with antifungal use in any of the patient groups.
This suggests that ASP programs are likely not yet
incorporating antifungals into their post-prescription
reviews, they are not implemented effectively, and/or
this marker was not an accurate reflection of the extent
of ASP and antifungal stewardship practices. Formulary
restriction is another recommended activity for an ASP
and our exploratory analysis regarding the effect of
restriction on antifungal use provided interesting in-
sights. Institutions that restricted echinocandins had
significantly higher total antifungal utilization in the
adult patient group despite a similar number of IFIs.
This was an unexpected finding and deserves additional
analysis to identify possible causes. Some restrictions
Table 4 Antifungal use among overall patient groups and the adult group by hospital echinocandin restriction
Agent Overall Adults
Restriction:
n = 43
No Restriction:
n = 17
p-value
(t-ratio or Z-statistic)
Restriction:
n = 43
No Restriction:
n = 17
p-value
(t-ratio)
Fluconazole 29.4 (24.5 to 34.3) 28.8 (22.5 to 35) 0.16a (0.48) 39 (34 to 44.2) 36 (24.2 to 45.2) 0.15b (0.8)
Echinocandins 10.9 (8 to 14) 8.6 (4.8 to 12.4) 0.34a (−0.9) 15 (12 to 18.4) 12 (8.5 to 15.7) 0.41b (1.3)
All Antifungals 53.7 (43.1 to 64.4) 49.7 (35.8 to 63.5) 0.3a (−0.08) 76 (63.6 to 89) 66 (44 to 88.4) < 0.001b (0.83)
Invasive Fungal Infections 0.72 (0.55 to 0.9) 0.65 (0.53 to 0.77) 0.538b (1.41) 0.81 (0.65 to 0.97) 0.72 (0.57 to 0.86) 0.3934b (0.57)
Antifungal data presented as mean (95% CI) days of therapy/1000 patient days
Invasive fungal infections data presented as mean (SD) admissions/1000 patient days
a Wilcoxon rank sum compared hospitals restricting echinocandins to those without restrictions
b T-test compared hospitals restricting echinocandins to those without restrictions
Bolded p-values were statistically significant
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may be in place due to cost versus based on appropriate
usage. Additionally, the difference was not noted in
overall patient groups after including the pediatric and
neonatal population, which may suggest differences in
usage policies between the neonatal, pediatric, and adult
populations within the included hospitals. Further ana-
lysis regarding the effectiveness and reasons behind anti-
fungal stewardship restrictions is needed.
Our study has some limitations. The data analyzed
were hospital-level and thus details of the indications for
antifungal use could not be readily obtained. However,
hospital-level data has the advantage of looking at a
larger population of patients at multiple centers and has
been used in previous studies [11, 22]. The use of ICD-9
codes for IFIs may not be the most accurate means of
identifying all patients with fungal infections, although
their designation was associated with use in the adult
group. The survey questions may not have accurately
reflected ASP involvement at an institution, although
this may be the only means by which this data can be
acquired. An exact survey response rate could not be
calculated because the survey was sent out to multiple
people at the same institution and not all hospitals who
received the survey had completed 2015 antifungal data.
Importantly, only unique hospital responses were in-
cluded for analysis. We excluded hospitals only provid-
ing care for hematology/oncology patients to ensure a
more homogeneous set of institutions, but antifungal
use is likely different in these institutions and this serves
as an area for future analysis.
Conclusions
In AMCs, there are differences in antifungal utilization
between neonatal, pediatric, and adult patient groups.
Factors associated with antifungal use were not able to
be identified for the neonatal patient group and this
suggested a wide variation in practices due to unknown
factors and a need for antifungal stewardship in this
area. In the pediatric and adult patient groups admission
to immunosuppressed service lines and broad-spectrum
antibiotic use were positive factors associated with
antifungal use. Review of antibacterial and antifungal
regimens by ASPs, especially among the immunosup-
pressed, could serve as a useful strategy towards ensur-
ing optimal use of antifungal agents.
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